Combination Immunotherapy

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman, Seth M. Steinberg, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 91; DOI: 10.1186/s40425-018-0409-8
Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade
Minghao Sui, Yu Li, Hongguang Wang, Ying Luo, Tao Wan, Xun Wang, Bingyang Hu, Yanshuang Cheng, Xianrong Lv, Xianlei Xin, Qiang Xu, Guan Wang, Shichun Lu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 125; DOI: 10.1186/s40425-019-0596-y
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
Julie Voeller, Amy K. Erbe, Jacob Slowinski, Kayla Rasmussen, Peter M. Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John Maris, Jacquelyn A. Hank, Zachary S. Morris, Alexander L. Rakhmilevich, Paul M. Sondel

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 344; DOI: 10.1186/s40425-019-0823-6
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman, Alejandro A. Gru, Craig L. Slingluff, Elizabeth M. Gaughan

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 94; DOI: 10.1186/s40425-016-0199-9
A New VISTA on combination therapy for negative checkpoint regulator blockade
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J. Noelle

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 86; DOI: 10.1186/s40425-016-0190-5
Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
George Fromm, Jason Rose, Suresh Desilva, Taylor Schreiber

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P371; DOI: 10.1186/2051-1426-3-S2-P371
Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
Antonia MS Mueller, Jonathan Hebb, Idit Sagiv-Barfi, Aurelien Marabelle, Roch Houot, Amanda Rajapaksa, Debra K Czerwinski, Serena Chang, Cariad Chester, Mohith Sadaram, Erin Waller, Ronald Levy, Holbrook Kohrt

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P106; DOI: 10.1186/2051-1426-2-S3-P106
Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
Sachin Puri, Jing Han, Bharat H Joshi, Daniel Healy, Janet Siebert, Christopher Paustian, Christopher Dubay, Keith S Bahjat, Brendan Curti, Walter J Urba, Bernard A Fox

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P257; DOI: 10.1186/2051-1426-2-S3-P257
Synergistic induction of cancer-related immunosuppression by β2-adrenergic stress mediators and P38MAPK inflammatory pathway
Ravikumar Muthuswamy, Frank Jenkins, Dana Bovbjerg, Pawel Kalinski

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P191; DOI: 10.1186/2051-1426-1-S1-P191
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P87; DOI: 10.1186/2051-1426-1-S1-P87

Main menu

Combination Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Combination Immunotherapy

Pages